We have investigated the role of the NFkB complex in the process of thyroid carcinogenesis by analysing thyroid carcinoma cell lines. A signi®cant increase in p65 NFkB mRNA and protein expression, compared to normal thyroid cultures or tissue, was found in all of the cancer cell lines. Conversely, only a modest increase in the p50 NFkB mRNA and protein was found in most, but not all carcinoma cell lines. The block of p65 protein synthesis with speci®c antisense oligonucleotides greatly reduced the ability of two undierentiated carcinoma cell lines to form colonies in agar and reduced their growth rate. On the other hand, no eect was observed in the same cell lines when treated with p50 speci®c antisense oligonucleotides. These inhibitory eects seem to be mediated by the suppression of c-myc gene expression, since treatment with antisense oligonucleotides for p65 gene interfered negatively with c-myc gene expression. Our results indicate that activation of the NFkB complex by overexpression of p65 plays a critical role in the process of thyroid cell transformation.
Introduction
The NFkB transcription complex exerts pleiotropic regulatory eects on the expression of an array of cellular genes that are induced in response to various growth factors, mitogens, tumor promoters, DNA damaging agents or oxygen radicals (Lenardo and Baltimore, 1989; Baeuerle, 1991; Baeuerle and Baltimore, 1991; Grimm and Baeuerle, 1993; Liou et al., 1994) . The active NFkB complex is composed of two subunits designated p50 and p65. The genes encoding p50 and p65 have been cloned and the N-terminal of both proteins show considerable homology to the product of the oncogene rel.
When the NFkB family members associate to form homodimers or heterodimers, their eciency of DNA binding and ability to transactivate a target sequence are determined by the speci®c factors that make up the complex. Dimerization of two proteins is required to provide an eective DNA binding domain. Homodimers of p50 bind strongly to DNA but are essentially unable to transactivate because p50 lacks an activation domain. Contrarily, homodimers of p65 bind weakly to DNA and are capable of transactivation (Nolan et al., 1991; Schmid et al., 1991; Schmitz and Bauerle, 1991; Bours et al., 1992; Ruben et al., 1992; Ryseck et al., 1992) .
Previous data demonstrate that inhibition of the p65 subunit by antisense technology elicits a strong block in the adhesion of several cell types, in vitro growth and tumorigenicity in athymic mice. Conversely, the inhibition of p50 has no eect on the adhesion of most cell types. However, in the murine ES cell system, the p50 antisense oligonucleotides inhibit cell adhesion in a dierentiation-dependent manner, since adhesion properties of these cells were aected after removal of leukemia-inhibiting factor, a growth factor which suppresses embryonic stem cell dierentiation Narayanan et al., 1993) .
The aim of our work has been to study possible alterations in the expression of the NFkB complex in thyroid carcinoma cell lines and to examine how these modi®cations might be important in the process of thyroid carcinogenesis. The use of the thyroid model might represent an important extension of the previous studies, since thyroid neoplasias include a broad spectrum of tumors with dierent phenotypic characteristics and dierent biological and clinical behaviour from the benign colloid adenomas through the slowly progressive dierentiated papillary and follicular carcinomas to the fatal anaplastic carcinomas (Hedinger et al., 1989) . Moreover several thyroid carcinoma cell lines are available showing dierent malignant phenotype (Cerutti et al., 1996) .
The results reported here demonstrate that increased NFkB activity is associated with an augmented expression of the p65 subunit in thyroid carcinoma cell lines. Moreover, antisense inhibition of the p65 subunit of the NFkB complex reduces the ability of two anaplastic thyroid carcinoma cell lines to form colonies in soft agar, which represents one of the main features of the neoplastic phenotype.
Results

Analysis of the NFkB activity in human thyroid carcinoma cell lines
Two normal human thyroid cell lines (HTC 1 and HTC 2) and seven thyroid carcinoma cell lines (four derived from papillary carcinomas: B-CPAP, NPA, TPC-1 and NIM 1; two from anaplastic carcinomas: FRO and ARO and one from a follicular carcinoma: WRO) were analysed for NFkB activity by electrophoretic mobility shift assay (EMSA) using an oligo speci®c for the NFkB activity as a probe (Figure 1 a  and b) . The human thyroid normal cells (HTC 1 and 2) were kept in culture for 10 and 30 passages, respectively. Therefore the HTC 2 cells might be considered a long-term culture. The results demonstrate that in all the carcinoma cell lines there is an increase of the NFkB binding activity compared to normal thyroid cells (Figure 1a , lane 1 and b, lane 7). The highest increase in NFkB activity was observed in the TPC-1 cell line (Figure 1a , lane 5 and b, lane 9). The binding activity of the dierent nuclear extracts was normalized by the use of an oligonucleotide probe binding to the ubiquitous Sp1 transcription factor (Figure 1c and d) . Densitometric analysis con®rmed that NFkB binding activity was signi®cantly augmented in thyroid carcinoma cell lines compared to the normal thyroid cells (2 ± 10-fold).
p50 and p65 gene expression in thyroid cells
To further investigate the NFkB changes in thyroid transformed cells, we analysed whole and nuclear cell lysates for the p65 and p50 protein levels by Western blot analysis in six carcinoma cell lines (ARO, FRO, B-CPAP, NPA, TPC-1 and NIM 1) and in normal human thyroid cells (HTC 1 and HTC 2) (Figures 2  and 3 ). The level of p65 protein was higher in both nuclear and whole lysates in all of the six carcinoma cell lines, particularly in the TPC-1 cell line. The p50 protein levels showed an increased expression in the majority of the cell lines compared to normal thyroid cells (Figure 2 ). The B-CPAP and ARO cells showed levels of p50 expression almost identical to that found in normal thyroid cells. Since the nuclear localization of p65 is regulated by IkBa, we measured its protein levels in the cytoplasmic extracts. As shown in Figure  3 , almost identical IkBa levels were detected in normal and carcinoma cell lines.
For each Western blot analysis, a parallel gel was run and stained with Coomassie blue to ascertain equal loading of the protein lysates (data not shown). Subsequently, we analysed the expression of the p50 and p65 genes in the same cell lines. The results, shown in Figure 4 , demonstrate that both genes are expressed at low levels in normal thyroid cells. Consistent with the increase in NFkB binding activity, levels of p65 transcripts were much higher in all of the thyroid carcinoma cell lines than in normal human thyroid tissue and cultured cells; the highest increase in p65 gene expression being observed in the TPC-1 cell line. Conversely, the increase in the expression level of p50 was much lower, and was not present in all of the thyroid carcinoma cell lines. In fact, in B-CPAP, FRO and ARO cells the p50 gene expression was comparable to that observed in normal thyroid tissue and cells. No p65 gene ampli®cation was observed in TPC-1 and ARO cells by Southern blot hybridization, suggesting that its overexpression is not due to gene ampli®cation (data not shown).
The eect of p65 and p50 protein synthesis inhibition on the proliferation of thyroid carcinoma cell lines
We next determined the role of p50 and p65 proteins in the process of cell transformation and growth by blocking their synthesis using antisense oligonucleotides. In particular, we used oligonucleotides directed against the 5' ends of the respective mRNAs (including three nucleotides upstream of the initiation codon). The eciency of these antisense oligonucleotides in blocking NFkB protein synthesis has previously been demonstrated Narayanan et al., 1993) . First, we evaluated in our cell system the ecacy of these oligonucleotides by treating the ARO cells with them and measuring p50 and p65 speci®c mRNA levels by Northern blot 72 h later. The p65 speci®c mRNA levels were signi®cantly (at least tenfold) lower in the ARO cells treated with the p65 antisense speci®c oligonucleotide ( Figure 5 , lane 3) than in the untreated ARO cells (lane 1) or treated with the p65 sense oligonucleotide (lane 2). Almost identical results were obtained with the p50 antisense oligonucleotide (data not shown).
To evaluate on thyroid malignant phenotype the consequence of block of NFkB complex, the eciency of clone formation in soft agar was evaluated in ARO and FRO cells treated with p50 and p65 sense and antisense oligonucleotides: a signi®cant reduction in the ability of both cell lines to grow in semisolid medium was induced by treatment with the p65 antisense oligonucleotide. In contrast, almost no eect was observed in the presence of the p50 antisense oligonucleotide. The correspondent sense oligonucleotides were used as a control (Figures 6 and 7) .
The eects of the p50 and p65 antisense oligonucleotides on the growth of the ARO and FRO cells were analysed by evaluating the DNA synthesis, measured as [ 3 H]thymidine incorporation after exposure to the oligonucleotides for 24 and 72 h.
Treatment with antisense p65 oligonucleotides signi®cantly reduced the thymidine incorporation by the ARO and FRO cells (Table 1) . Moreover, inhibition of thymidine incorporation augmented with increasing concentrations of antisense p65 oligonucleotide (data not shown). These eects were speci®c for transformed cells. Indeed p65 antisense oligonucleotide exerted no inhibitory eect on the rate of DNA synthesis of HTC 1 (Table 1) . These dierences were not due to a dierent uptake of the antisense oligonucleotides by normal and neoplastic cells, because both cell types showed comparable uptake of the oligonucleotides (Table 2) . Treatment of the same cells with p50 antisense oligonucleotide does not have any eect on cell growth (data not shown).
Myc downregulation by p65 antisense oligonucleotide
In order to understand the molecular mechanisms by which the p65 antisense oligonucleotide blocks thyroid Figure 6 Colony-forming ability of the ARO cells in the presence of p50 and p65 sense and antisense speci®c oligonucleotides. The cells were exposed to 8 mM sense or antisense oligonucleotides or left untreated before plating in soft agar. The colonies were counted after 10 days Figure 7 Colony-forming ability of the FRO cells in the presence of p50 and p65 sense and antisense speci®c oligonucleotides. The cells were exposed to 8 mM sense or antisense oligonucleotides or left untreated before plating in soft agar. The colonies were counted after 10 days cells growth and malignancy, we analysed the expression of genes potentially important in the process of thyroid cell transformation in ARO cells treated with p65 sense and antisense oligonucleotide by Northern blot. First, we analysed the expression of the c-myc proto-oncogene, it being well known that the ®rst regulatory exon of c-myc contains sequences that are susceptible to transactivation by the NFkB complex. Moreover, it has recently been demonstrated that p65 and, to a lower extent, p50 are able to transactivate the c-myc promoter (La Rosa et al., 1994) . The results, shown in Figure 5 , indicate a signi®cant reduction (at least fourfold) of c-myc speci®c mRNA levels. The expression of the HMGI(Y) gene, coding for the high mobility group proteins HMGI and HMGY, whose expression is known to be correlated to the neoplastic phenotype (Giancotti et al., 1985 (Giancotti et al., , 1987 Bussemakers et al., 1991; Chiappetta et al., 1995) , resulted also decreased (at least threefold) in the antisense treated cells. Conversely, expression of the Vascular Endothelial Growth Factor (VEGF) gene, which has been demonstrated to be overexpressed in thyroid carcinoma cell lines (Viglietto et al., 1995) and it is known to be regulated by the AP-1 transcriptional complex (Saez et al., 1995) , is not signi®cantly modi®ed by the p65 antisense oligonucleotide.
Discussion
In the study presented here, we analysed the role of the NFkB transcription complex in the process of thyroid carcinogenesis. We found a high expression of the p65 gene and protein in all seven human thyroid carcinoma cell lines compared to normal thyroid cells. However, no precise correlation has been found between the increased p65 levels and the degree of malignant phenotype observed in the cell lines. In fact, the ARO cells, which showed a highly malignant phenotype, showed lower expression level of p65 than the TPC-1 cell line, which is derived from a papillary thyroid carcinoma, and is only weakly tumorigenic after injection into athymic mice. This ®nding is not in contrast with the role played in thyroid cell transformation by the NFkB induced activity, since it is reasonable that the degree of the malignant phenotype is given by combined alterations of several transcriptional factors.
The increased NFkB activity seems to depend on the accumulation of the p65 protein in thyroid carcinoma cell lines. The p65 protein levels were found increased, both in whole and nuclear lysates, and they essentially correlate with speci®c mRNA levels, indicating that the upregulated expression of p65 mRNA in thyroid carcinoma cell lines is responsible for the NFkB increased activity.
The p50 expression increased only in some transformed thyroid cells and this increase was much lower compared to that of p65. Moreover, some cell lines, such as B-CPAP, ARO and FRO, did not exhibit any increase in p50 expression. Conversely, the IkBa protein, which regulates the nuclear localization of p65, is present at comparable levels in the cytoplasmic extracts of normal and transformed cells.
It is very interesting to observe that the highest level of p65 and p50 expression has been found in the TPC-1 cell line, which harbours the RET/PTC 1 lesion that is typical of the human papillary thyroid carcinoma (Grieco et al., 1990; Santoro et al., 1992) . This might suggest an interference of the RET/PTC transduction pathway on the NFkB activity. However, the increase in the NFkB activity has been found in all of the carcinoma cell lines, independently from their tumor histotype and genetic lesion, suggesting that NFkB activation is a common event in the process of cell transformation. This seems to be con®rmed by preliminary data showing analogous modi®cations in rat thyroid cell lines transformed by the v-mos and vKi-ras oncogenes (Visconti and Fusco, unpublished results).
Thyroid carcinomas comprise a broad spectrum of tumors with dierent clinical behaviours. On one side, there are occult papillary carcinomas, which are slow growing and clinically silent carcinomas, and on the other side, rapidly growing anaplastic carcinomas, among the most lethal human neoplasms. Anaplastic thyroid carcinomas represent a very aggressive neoplasia, resistent to any therapeutic approach, and that invariably lead to the death of the patients within a few months.
Since it has previously been demonstrated that the exposure of several adherent transformed murine ®broblasts and human tumor cell lines to p65 antisense oligonucleotide induces cell growth inhibition , we investigated whether the p65 antisense oligonucleotide might be considered a potential therapeutic agent and if it may be used as a new drug for the treatment of anaplastic thyroid carcinomas. Therefore, we have exposed two anaplastic thyroid cell lines, FRO and ARO, to this oligonucleotide. Treatment with the p65 antisense oligonucleotide signi®cantly blocked their growth in agar (more than 50%) and Thymidine incorporation (about 40%). The eect was speci®c for this oligonucleotide, with no signi®cant eects on the growth and malignancy of thyroid carcinoma cell lines being observed with the p50 antisense oligonucleotide. These data, even though con®rmatory of those reported by Higgins et al. and Narayanan et al. , extend them to a well de®ned epithelial cell system. Moreover, these results might stimulate the use of p65 antisense oligonucleotide in the treatment of experimental thyroid tumors. The achievement of analogous results also in vivo might suggest an antisense methodology, based on p65 antisense oligonucleotide, as an approach for the treatment of this kind of cancer.
As far as the mechanism of cell growth inhibition by p65 antisense oligonucleotide is concerned, a signi®cant reduction in the level of c-myc proto-oncogene expression in ARO and FRO cells treated with the p65 antisense oligonucleotide was observed. This result might account, at least partially, for the inhibitory growth eects induced by the block of p65 protein synthesis. In fact, our group has previously demonstrated that c-myc overexpression is present in all of the thyroid carcinoma cell lines analysed and treatment of the ARO and FRO cells with c-myc speci®c antisense oligonucleotide was able to drastically reduce their ability to grow in soft agar (Cerutti et al., 1996) .
The reduction of HMGI(Y) gene expression after p65 antisense oligonucleotide treatment in ARO cells might also account for the inhibitory growth eect. In fact, expression of the HMGI proteins is highly elevated in transformed cells, and a correlation was found between the levels of HMGI protein expression and the degree of malignant phenotype (Giancotti et al., 1985 (Giancotti et al., , 1987 Bussemakers et al., 1991; . Indeed, blocking HMGI protein expression prevents thyroid cell transformation by both v-mos and v-ras-Ki oncogenes . Conversely, no modi®cation of the VEGF expression was observed in the p65 antisense treated ARO cells indicating that, in our cell system, the block of the p65 protein does not seem to interfere on the AP-1 complex activity, which is known to regulate the VEGF gene expression (Saez et al., 1995) .
In conclusion, inhibition of the proliferation of human thyroid carcinoma cell lines by p65 speci®c antisense oligonucleotide strongly indicates a role of p65 overexpression in the process of human thyroid carcinogenesis.
Materials and methods
Cell culture and assay of the transformed state
The human thyroid carcinoma cell lines studied were: TPC-1 (Tanaka et al., 1987) , WRO (Pang et al., 1989) , NPA (Estour et al., 1989) , ARO (Pang et al., 1989) , FRO (Fagin et al., 1993) , NIM 1 (Zeki et al., 1991) and B-CPAP (Fabien et al., 1994) . They were grown in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% fetal bovine serum. HTC 1 and HTC 2 were established and culture as described (Curcio et al., 1994) . They got 10 and 30 passages, respectively. The B-CPAP cells used for these experiments were frozen at the tenth passage. Soft agar colony assays were performed as described elsewhere (Macpherson and Montagnier, 1964) .
RNA isolation and northern blot analyses
Total RNA extractions, Northern blots and hybridizations were performed according to standard procedures (Sambrook et al., 1989) .
The p65 probe was a fragment prepared from the plasmid pMT2Tp65 (described in Bours et al., 1992 ) the p50 probe was the 1.6 Kb HindIII ± XbaI fragment of pMT2Tp50.
The c-myc probe used in this study was the 1.3 Kb PstI ± PstI fragment of the pRyc 7.4 plasmid (Nishikura et al., 1983) . The HMGI(Y) probe used was a 612 bp PstI ± EcoRI fragment obtained from the pHMGI(Y) plasmid (Johnson et al., 1988) . The VEGF probe was a 0.6 Kb EcoRI ± BamHI fragment of the plasmid speci®c for the human VEGF cDNA (Viglietto et al., 1995) . A mouse b actin probe was used to ascertain equal RNA loading (Tokunaga et al., 1986) .
Nuclear extracts and EMSA
Normal and carcinoma thyroid cell lines, nuclear extracts and the analysis of DNA protein complexes were carried out as described (Wu, 1985; Fried and Crothers, 1981) . Brie¯y, a synthetic oligonucleotide (21mer) containing the NFkB responsive element 5'-CGC TTG ATG AGT CAG CCG GAA-3' was used as probe for the EMSA. This oligonucleotide (purchased from Promega corporation, USA) was 5'-end labeled with T4 polynucleotide kinase and [g-32 P]ATP and annealed with the complementary strand. Nuclear extracts were preincubated for 5 min on ice in 10 mM HEPES (pH 7.9), 50 mM NaCl, 0.1 mM ethylenediaminetetraacetic acid (EDTA), 5 mM dithiothreitol (DTT), 0.1 mM phenylmethyl-sulfonyl¯uoride (PMSF), 5% glycerol, 5 mM spermidine, 2 mg of poly(dI-dC) and 4 mg of salmon sperm DNA. When unlabeled DNA fragments were added as competitors, the reaction was pre-incubated for 10 min at room temperature before adding the labeled DNA. As a control of speci®city, a synthetic oligonucleotide containing three Sp1 consensus sequences (5'-GGGGCGGGGCGGGGCGGGGCGGGG-CGGGGC-3') was used.
Protein isolation and Western immunoblot analysis
The protein isolation procedure has been described elsewhere (Francis-Lang et al., 1992) : 5610 6 cells were washed twice with PBS, then lysed in a buer containing 10 mM sodium phosphate (pH 7.4), 0.1 M NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 1 mM PMSF, 10 mg of aprotinin/ml, 10 mg of leupeptine/ml and 10 mg of pepstatin/ml. Extracts were clari®ed by sedimentation in a microcentrifuge at low speed for 5 min at 48C. The protein concentration of the supernatant was determined by the Bio-Rad protein microassay as speci®ed by the manufacturer (Bio-Rad, Warford-England).
The cytoplasmic proteins isolation procedure was: 2610 6 cells were washed twice with PBS, then lysed in a buer containing 10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.1 mM b-aminoethyl ether N,N,N',N'-tetraacetic acid (EGTA) pH 7, 1 mM PMSF and 0.5 mM DTT. Extracts were clari®ed by sedimentation in a microcentrifuge at low speed for 5 min at 48C. Supernatants were loaded on a 10% SDS polyacrilamide gel for Western immunoblot analysis. Western immunoblot analysis was performed according to a standard procedure (Harlow and Lane, 1989) . Brie¯y, protein fractionation was carried by a 10% SDS-polyacrylamide gel electrophoresis using 80 mg of cell protein samples per lane. Before loading, proteins were diluted in loading buer containing 10% glycerol, 2% SDS, 62.5 mM Tris-HCl pH 6.8, 5% b-mercaptoethanol, 0.5% bromophenol blue. Gels were transferred to nitrocellulose in transfer buer (390 mM glycine, 480 mM Tris, 20% methanol). The ®lters were incubated for 1 h at room temperature in 1% non fat dried milk (NFDM) and TBS buer (200 mM Tris-HCl pH 7.9, 1.5 M NaCl). After washing, the ®lters were incubated for 1 h in TTBS buer (200 mM Tris-HCl pH 7.9, 1.5 M NaCl, 0.5% Tween) plus 1% NFDM containing 10 mg/ml of the speci®c antibody. After four washes, blots were incubated with antirabbit antibodies conjugated with horseradish peroxidase diluted 1 : 1000 for 1 h in TTBS plus 1% NFDM. Parallel gels were run to ascertain that equal amounts of protein had in fact been loaded by staining with Coomassie blue. Detection of bound antibody was performed with ECL (Western blot detection kit, Amersham). The antibodies anti p50 and p65 were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, California).
Eects of antisense oligonucleotides on cell growth in semisolid medium
The oligonucleotide sequences used corresponded to the 5'-ends of the respective mRNAs.
The p65 oligomer used was 5'-GCC ATG GAC GAA CTG TTC CCC-3', the antisense oligomer was 5'-GGG GAA CAG TTC GTC CAT GGC-3' (Holt et al., 1988) . The p50 oligomer used was 5'-AGA ATG GCA GAA GAT GAT CCA-3', the antisense oligomer was 5'-TGG ATC ATC TTC TGC CAT TCT-3'.
Phosphorothioate oligonucleotides were purchased from Eurogentec (Liegi, Belgium). They were synthesized by a modi®cation of the H-phosphonate procedure (Stein et al., 1988) and puri®ed by ion-exchange chromatography and ethanol precipitated.
To analyse the ability of the antisense oligonucleotides to aect the expression of p50 and p65 NFkB mRNAs, the cells were treated with 4 mM of oligonucleotide 24 h after cell plating. Total RNAs were extracted 72 h after oligonucleotide treatment, and the levels of the p50 and p65 gene expression were analysed by Northern blot.
To analyse the eects of antisense oligonucleotides on growth in agar, the cells were treated for 48 h with the oligonucleotides at the concentrations indicated above, the cells were subsequently plated in agar according to an already published procedure (MacPherson and Montagnier, 1964) .
DNA synthesis assay
To evaluate the eects of the oligonucleotides on the cell growth rate, 10 5 cells were plated and 15 h later were treated with sense or antisense oligomers. After 24 and 72 h, DNA synthesis was measured by incorporation of [ 3 H]thymidine (2 microCi/ml; 40 Ci/mmol; Amersham) into trichloacetic acid-insoluble material as described elsewhere (Iacovelli et al., 1993) . The results are expressed as percentage of inhibition of Thymidine incorporation in comparison to untreated cells. Each value is the mean of at least three experiments in duplicate. Thymidine uptake values were analysed by one way ANOVA. Dierences were considered statistically signi®cant if P was 50.05. 
